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Abstract 
Purpose: To examine the effectiveness of Resina Draconis capsules in the treatment of primary 
dysmenorrhoea. 
Methods: In total, 324 patients with primary dysmenorrhoea were randomly allocated to three groups 
based on treatment with capsules containing Resina Draconis, Leonurus japonicus Houtt., or a placebo 
for 3 months. The patients’ visual analogue scale (VAS) scores and dysmenorrhoea symptoms were 
evaluated. 
Results: VAS scores of the Resina Draconis, L. japonicus, and placebo groups decreased from 7.31 ± 
1.36, 7.12 ± 1.65, and 7.25 ± 1.47 to 3.35 ± 1.43, 5.27 ± 1.24, and 7.08 ± 2.10, respectively. The 
change was greatest for the Resina Draconis group (p < 0.01). The incidence of symptoms associated 
with dysmenorrhoea decreased in all three groups, but the change was greatest for Resina Draconis 
group (p < 0.01). Overall, Resina Draconis was more effective than L. japonicus (94.40 vs. 72.20 %) (p 
< 0.05). 
Conclusion: Resina Draconis capsules are effective in relieving primary dysmenorrhoea and lowering 
the incidence of symptoms associated with dysmenorrhoea. 
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Dysmenorrhoea is a common gynaecological 
disease that can be classified into primary and 
secondary dysmenorrhoea. Primary 
dysmenorrhoea, or functional dysmenorrhoea, 
refers to pain, bloating, and discomfort in the 
lower abdomen before and after menstruation or 
during menstruation when there is no organic 
disease in the reproductive organs. In severe 
cases, it can even lead to nausea, emesis, cold 
hands and feet, and syncope. The estimated 
incidence of primary dysmenorrhoea in China is 
36 % [1,2]. The occurrence of primary 
dysmenorrhoea is correlated with prostaglandin 
released by the endometrium during 
menstruation; the prostaglandin levels in the 
endometrium and menstrual blood of women with 
dysmenorrhoea are higher than in healthy 
women [3]. Primary dysmenorrhoea usually 
occurs 6 – 12 months after the first menstrual 
cycle [4]. 
 
The pathogenesis of primary dysmenorrhoea is 
complex and includes mental and neural factors. 
It can also be induced by uterine ischemia 
caused by the spasmodic contraction of uterine 
muscle. Uterine contractions stimulated by the 
retention of menstrual blood resulting from 
uterine dysgenesis, a narrowed cervix, or uterine 
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hyperflexion, may also lead to primary 
dysmenorrhoea [5]. The incidence of primary 
dysmenorrhoea has increased in recent years, 
impacting the quality of life for affected women 
[6]. Primary dysmenorrhoea usually disappears 
after a delivery. 
 
The main components of Resina Draconis 
capsules include Resina Draconis, pseudo-
ginseng, and borneol [7]. In traditional Chinese 
medicine, Qi controls the blood and blood is the 
mother of Qi; stasis is eliminated when blood 
circulates, and blood circulates when Qi is active. 
Resina Draconis, a red resin produced by plants 
of the genus Dracaena Vand. ex L, has a long 
history of use in China. It is believed to function 
in activating blood, eliminating stasis, relieving 
swelling and pain, and stopping bleeding [8]. 
Resina Draconis capsules contain several active 
ingredients, including Resina Draconis, saponins, 
and plant defensins, which have double 
regulatory effects. Although there are many 
treatments for primary dysmenorrhoea, few 
studies have examined treatment with Resina 
Draconis. This study examined the use and 
clinical effects of Resina Draconis capsules in 




Study setting and patient characteristics 
 
In total, 324 patients with confirmed primary 
dysmenorrhoea in Binzhou Medical University 
Hospital, Shandong, China, were enrolled in this 
study, which was approved by the medical ethics 
committee of Binzhou Medical University 
Hospital (approval no. BMUHSL20150425) and 
conducted according to the tenets of the 
Declaration of Helsinki [9]. 
 
The enrolled patients had no organic lesions in 
their reproductive organs, based on B-mode 
ultrasonography, had menstrual cycles of 23 – 35 
days, and provided written informed consent. 
Patients were excluded if they were pregnant or 
breastfeeding, if they had a mental illness or a 
major disease related to the heart, liver, kidney, 
or haemopoietic systems, or if they were allergic 
to the drugs. The enrolled patients were 
allocated randomly to Resina Draconis, Leonurus 
japonicus Houtt., and placebo treatment groups 
(n = 108 per group).  
 
Subjects in the Resina Draconis group had an 
average age of 28 ± 5.70 (range 15 – 35) years 
and disease duration of 3.40 ± 2 (range 2 – 6) 
years, 78 were single and 30 were married, 60 
patients had previously been pregnant, and 18, 
60, and 30 patients had mild, moderate, and 
severe dysmenorrhoea, respectively. In the L. 
japonicus group, the average age was 28.10 ± 
6.30 (range 14 – 32) years and the disease 
duration was 4 ± 2.40 (range 1 – 6) years, 66 
patients were single and 42 were married; 66 
patients had previously been pregnant, and 30, 
60 and 18 patients had mild, moderate, and 
severe dysmenorrhoea, respectively. In the 
placebo group, the average patient age was 
29.30 ± 6.70 (range 13 – 36) years and the 
average disease duration was 3.60 ± 2.20 (range 
2 – 5) years; 69 patients were single and 39 were 
married, 63 patients had previously been 
pregnant, and 24, 72 and 12 patients had mild, 
moderate, and severe dysmenorrhoea, 
respectively. None of the differences among the 




Each patient in the Resina Draconis group was 
given two Resina Draconis capsules (Yunhe 
Pharmaceutical, Yunnan, China; main 
component: Resina Draconis, auxiliary 
components: starch, sodium carboxymethyl 
starch, and lactose) three times daily. Each 
member of the L. japonicus group was given one 
L. japonicus Houtt. capsule (Shenyang Yongda 
Pharmaceutical, Liaoning, China; main 
component: L. japonicus Houtt.) three times 
daily. Each patient in the placebo group was 
given a single placebo capsule (Kangyuan 
Pharmaceutical, Jiangsu, China; main 
components: lactose and a pigment), three times 
daily. The capsules were taken orally for 1 week 
each month, beginning 3 days before the 




The patients used a visual analogue scale (VAS) 
to score their pain before and after treatment. 
The scale ranged from 0 to 10 points, with 0 
points indicating no pain and 10 points 
intolerable pain. The relief of dysmenorrhoea 
symptoms (e.g., lower abdominal pain and 
distension, lower abdominal crymodynia, 
premenstrual breast swelling, cold limbs, and 
nausea and vomiting), the presence of blood in 
urine, stool indexes; and liver and kidney 
functions were observed in all three groups. After 
treatment, all patients were followed for 3 
months. The curative effect was compared 
among the three groups. 
 
Evaluation criteria for a cure 
 
Cure was defined as the disappearance of 
abdominal pain and other symptoms, and no 
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recurrence of disease after drug withdrawal. The 
result was marked if the patients had significantly 
reduced abdominal pain, if the other clinical 
symptoms disappeared or were reduced, and if 
they did not need to take analgesics. The 
treatment was considered effective if the patients 
experienced relief from symptoms associated 
with dysmenorrhoea and stopped taking 
analgesics. Treatment was considered ineffective 
if there were no changes in their symptoms and 




The data were analysed using the SPSS 
software (ver. 15.0) and compared using t-tests, 
one-way analysis of variance, and q tests. 
Enumerated data were assessed using the χ2 
test. Ordered categorical data were tested with 
the rank sum test. Differences were considered 




Comparison of VAS scores before and after 
treatment 
 
Before treatment, the differences in VAS scores 
among the three groups were not significant (p > 
0.05). The VAS scores before and after 
treatment did not differ in the placebo group (p > 
0.05). After treatment, the VAS scores of the 
Resina Draconis and L. japonicus groups were 
lower than that of the placebo group, and they 
were much lower for the Resina Draconis group 
(p < 0.05) (Table 1). 
 
Comparison of associated symptoms before 
and after treatment 
 
Before treatment, the incidence of symptoms 
associated with dysmenorrhoea, including 
abdominal pain and distension, abdominal 
crymodynia, premenstrual breast swelling, cold 
limbs, and nausea and vomiting, did not differ 
significantly among the three groups. After 
treatment, such symptoms were less frequent in 
the Resina Draconis and L. japonicus groups 
compared with the placebo group (p < 0.01). In 
addition, abdominal pain and distension, 
abdominal crymodynia, and nausea and vomiting 
were less frequent in the Resina Draconis group 
compared with the L. japonicus group after 
treatment (p < 0.05 or 0.01). The incidence of 
symptoms associated with dysmenorrhoea in the 
placebo group did not differ before and after 
treatment (p > 0.05) (Table 2). 
 
Comparison of clinical effect among the 
three groups 
 
At the 3-month follow-up visit, the curative effect 
differed significantly among the three groups (Hc 
= 58.461, p < 0.01); it was 94.4 % in the Resina 
Draconis group versus 72.2 % in the L. japonicus 
group (p < 0.05) (Table 3). 
 
 
Table 1: Comparison of the VAS scores before and after treatment (mean ± standard deviation [SD]) 
 
Group N Before After 
Resina Draconis 108 7.31±1.36 3.35±1.43abc 
Leonurus japonicus 108 7.12±1.65 5.27±1.24ab 
Placebo 108 7.25±1.47 7.08±2.10 
a P < 0.01 for within-group comparisons, b p < 0.01 compared with the placebo group 
after treatment, c p < 0.01 compared with the L. japonicus group after treatment 
 
Table 2: Comparison of symptoms associated with dysmenorrhoea before and after treatment (N, %) 
 
Symptom Resina draconis L. japonicus Placebo Before After Before After Before After 
Abdominal pain and distension 99 (91.70) 10 (13.90)abd 105 (97.20) 45 (41.70)ab 102 (94.40) 90 (83.30) 
Abdominal crymodynia 87 (89.60) 6 (8.30)abc 84 (77.80) 30 (27.80)ab 90 (83.30) 72 (66.70) 
Premenstrual breast swelling 84 (77.80) 10 (13.90)ab 81(75) 27(25)ab 87 (89.60) 84 (77.80) 
Cold limbs 96 (88.90) 10 (13.90)ab 99 (91.70) 36 (33.30)ab 87 (89.60) 81(75) 
Nausea and vomiting 87 (80.60) 6 (8.30)abd 84 (77.80) 42 (38.90)ab 87 (89.60) 84 (77.80) 
a P < 0.01 before and after treatment in the different groups, b p < 0.01 compared with the placebo group after 
treatment, c p < 0.05,  d p < 0.01 compared with the L. japonicus group after treatment 
 
Table 3: Comparison of the curative effect in the three groups (N, %) 
 
Group N Cure Marked effect Effective Ineffective 
Resina Draconis 108 30 (27.80) 54 (50) 18 (16.70) 6 (5.50) 
L. japonicus 108 27 (25) 39 (36.10) 12 (11.10) 30 (27.80) 
Placebo 108 0 0 0 108 (100) 
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Safety of drug use 
 
The patients in the three groups developed no 
obvious untoward reactions during treatment. In 
addition, blood, urine, and stool indexes and the 
renal and kidney functions of the patients in the 





Primary dysmenorrhoea, or functional 
dysmenorrhoea, occurs mostly in menarche and 
in nulliparous women. Patients with the disease 
have no obvious pathological changes to the 
reproductive organs on examination. The 
pathogenesis of primary dysmenorrhoea is 
unclear. Pathogenic factors contributing to the 
disease include uterine contraction 
abnormalities, cyclic changes in oestrogens and 
androgens in the menstrual cycle, and ischaemia 
and the stimulation of the nerve plexus of the 
uterine isthmus [10].  
 
During menstruation, the endometrium 
synthesises and releases more prostaglandins, 
which can lead to spasmodic uterine contractions 
and cause pain. Excessive uterine contractions 
are also correlated with oxytocin levels. About 
10% of women have primary dysmenorrhoea 
during their lifetime, and the incidence of primary 
dysmenorrhoea is increasing [11]. The treatment 
of primary dysmenorrhoea includes non-steroidal 
anti-inflammatory drugs to relieve the pain and 
spasms [12]. Although such drugs work rapidly, 
their side effects include gastrointestinal 
symptoms and a heavier menstrual flow, which 
can reduce acceptance of the drugs by patients 
[13]. 
 
In traditional Chinese medicine, the occurrence 
of dysmenorrhoea is associated with various 
factors [14–16], including catching a cold during 
the menstrual period, eating cold food, and sitting 
on wet ground. It can also be induced by liver Qi 
stagnation, weakness of the spleen and 
stomach, a congenital deficiency in Qi and the 
blood, as well as deficiencies of the liver and 
kidneys. The main symptoms of dysmenorrhoea 
of the congealing cold and blood stasis types are 
lower abdominal crymodynia, reduced blood 
volume, dark coloured blood, blood clots, cold 
limbs, a light or dark purple tongue, and a white 
furred tongue during the menstrual period. 
Catching a cold during the menstrual period or 
eating cold food can induce the invasion of cold 
pathogens and cold congealing in the uterus, 
and consequently block the circulation of Qi and 
blood. 
 
Resina draconis capsules can relieve or reduce 
the pain of patients with primary dysmenorrhoea, 
shorten the duration of dysmenorrhoea, and 
improve the syndromes of traditional Chinese 
medicine [17,18]. Leonurus japonicus can relieve 
the pain caused by dysmenorrhoea by 
restraining the activity of a spasmodic uterus, 
lowering the prostaglandin levels in smooth 
muscle, and increasing progesterone levels. The 
compounds loureirin and saponin in Resina 
draconis not only improve microcirculation, 
regulate metabolism, and enhance immune 
function, but also activate blood, eliminate blood 
stasis, and stop bleeding [19]. 
 
This study showed that, both Resina draconis 
and L. japonicus reduced the pain of patients 
with dysmenorrhoea, and Resina draconis was 
significantly better (p < 0.01). The incidences of 
abdominal pain and distension, lower abdominal 
crymodynia, and nausea and vomiting were 
lower in the Resina Draconis group than in the L. 




The sample size was relatively small due to 
limited time and the experimental conditions. In 
addition, the effects of diet and emotion on the 





Resina draconis capsules effectively relieved the 
pain associated with primary dysmenorrhoea and 
reduced the incidence of symptoms associated 
with dysmenorrhoea. Thus, Resina Draconis may 
potentially be useful in the clinical management 
of dysmenorrhoea, but further studies, including 
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